Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDQuarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2025 | 1 | -$0.12 | -$0.10 | -$0.11 |
Q2 2025 | 1 | -$0.11 | -$0.09 | -$0.10 |
Q3 2025 | 1 | -$0.09 | -$0.07 | -$0.08 |
Q4 2025 | 1 | -$0.09 | -$0.07 | -$0.08 |
Q1 2026 | 1 | -$0.11 | -$0.09 | -$0.10 |
Q2 2026 | 1 | -$0.10 | -$0.08 | -$0.09 |
Q3 2026 | 1 | -$0.07 | -$0.05 | -$0.06 |
Q4 2026 | 1 | -$0.05 | -$0.04 | -$0.04 |
MaxCyte, Inc. last posted its earnings results on Tuesday, March 11th, 2025. The company reported $-0.1 earnings per share for the quarter, topping analysts' consensus estimates of $-0.12 by $0.02. The company had revenue of 8.69 M for the quarter and had revenue of 38.63 M for the year. MaxCyte, Inc. has generated $0 earnings per share over the last year ($-0.39 diluted earnings per share) and currently has a price-to-earnings ratio of -8.18. MaxCyte, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, March 11th, 2025 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
03/11/2025 | Q4 2024 | -$0.12 | -$0.10 | 0.02 | $8.04 M | $8.69 M |
11/06/2024 | Q3 2024 | -$0.13 | -$0.11 | 0.02 | $7.46 M | $8.16 M |
08/06/2024 | Q2 2024 | -$0.14 | -$0.09 | 0.05 | $7.97 M | $10.43 M |
05/07/2024 | Q1 2024 | -$0.14 | -$0.09 | 0.05 | N/A | $11.34 M |
03/12/2024 | Q4 2023 | -$0.10 | -$0.05 | 0.05 | $13.44 M | $15.67 M |
11/08/2023 | Q3 2023 | -$0.10 | -$0.11 | -0.01 | $8.87 M | $8.00 M |
08/09/2023 | Q2 2023 | -$0.10 | -$0.10 | 0 | $10.66 M | $9.04 M |
05/10/2023 | Q1 2023 | -$0.11 | -$0.08 | 0.03 | N/A | $8.58 M |
03/15/2023 | Q4 2022 | -$0.06 | -$0.03 | 0.03 | N/A | $12.42 M |
11/09/2022 | Q3 2022 | -$0.09 | -$0.06 | 0.03 | $10.43 M | $10.64 M |
08/10/2022 | Q2 2022 | -$0.08 | -$0.08 | 0 | $9.23 M | $9.61 M |
05/09/2022 | Q1 2022 | -$0.07 | -$0.04 | 0.03 | N/A | $11.59 M |
03/22/2022 | Q4 2021 | -$0.05 | -$0.05 | 0 | N/A | $10.15 M |
11/10/2021 | Q3 2021 | -$0.05 | -$0.03 | 0.02 | $7.28 M | $10.14 M |
09/13/2021 | Q2 2021 | -$0.05 | -$0.05 | -0 | $5.79 M | $7.11 M |
03/31/2021 | Q1 2021 | N/A | -$0.09 | N/A | N/A | $6.49 M |
12/30/2020 | Q4 2020 | N/A | -$0.03 | N/A | N/A | $8.51 M |
09/29/2020 | Q3 2020 | N/A | -$0.04 | N/A | N/A | $6.76 M |
06/29/2020 | Q2 2020 | N/A | -$0.05 | N/A | $13.39 M | $5.15 M |
03/30/2020 | Q1 2020 | N/A | -$0.05 | N/A | N/A | $5.74 M |
MaxCyte, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, March 11th, 2025 based offlast year's report dates.
In the previous quarter, MaxCyte, Inc. (:MXCT) reported $-0.1 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.12 by $0.02.
The conference call for MaxCyte, Inc.'s latest earnings report can be listened to online.
The conference call transcript for MaxCyte, Inc.'s latest earnings report can be read online.
MaxCyte, Inc. (:MXCT) has a recorded annual revenue of $38.63 M.
MaxCyte, Inc. (:MXCT) has a recorded net income of $-41,055,000.MaxCyte, Inc. has generated $-0.39 earnings per share over the last four quarters.
MaxCyte, Inc. (:MXCT) has a price-to-earnings ratio of -8.18 and price/earnings-to-growth ratio is 0.56.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED